ArticlePloS one2020
Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- A major stakeholder in the lobbying efforts: the role of people who use drugs in the past and the current opioid crisis.BMC public health · 2025Article
- Optimizing placement of public-access naloxone kits using geospatial analytics: a modelling study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- Using illicit drugs alone in Vancouver, Canada: a gender-based analysis.Substance abuse treatment, prevention, and policy · 2025Article
- Improving racial/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community-based naloxone distribution strategies in Massachusetts, United States.Addiction (Abingdon, England) · 2025Article
- Article
- Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA.Addiction (Abingdon, England) · 2023Article
- Feasibility and Acceptability of an Overdose Prevention Intervention Delivered by Community Pharmacists for Patients Prescribed Opioids for Chronic Non-Cancer Pain.Pharmacy (Basel, Switzerland) · 2023Article
- Evaluation of a large-scale health department naloxone distribution program: Per capita naloxone distribution and overdose morality.PloS one · 2023Article
- Development of a neural network model to predict the presence of fentanyl in community drug samples.PloS one · 2023Article
- Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island.JAMA network open · 2022Article
- Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.Substance abuse treatment, prevention, and policy · 2022Article
- Characteristics of and Experience Among People Who Use Take-Home Naloxone in Skåne County, Sweden.Frontiers in public health · 2022Article
- Strategies Adopted by Addiction Facilities during the Coronavirus Pandemic to Support Treatment for Individuals in Recovery or Struggling with a Substance Use Disorder: A Scoping Review.International journal of environmental research and public health · 2021Article
- The implementation and role of a staff naloxone program for non-profit community-based sites in British Columbia: A descriptive study.PloS one · 2021Article
- A survey of Alberta pharmacists' attitudes, comfort and perceived barriers to a community-based naloxone program.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
introductionBritish Columbia's (BC) Take-Home Naloxone (THN) program provides naloxone to bystanders for use in cases of suspected opioid overdose. This study seeks to provide trends and analysis from the provincial BC THN program since inception in 2012 to the end of 2018. MATERIALS AND
methodsBC THN shipment and distribution records from 2012-2018 were retrieved. Frequency distributions were used to describe characteristics of individuals accessing the program. To evaluate correlates of distribution after the addition of hundreds of pharmacy distribution sites, an analytic sample was limited to records from 2018, and multivariate logistic regression was used to evaluate correlates of collecting naloxone at a pharmacy site.
resultsSince program inception to the end of 2018, there were 398,167 naloxone kits shipped to distribution sites, 149,999 kits reported distributed, and 40,903 kits reported used to reverse an overdose in BC. There was a significant increasing trend in the number of naloxone kits used to reverse an overdose over time (p<0.01), and more than 90% of kits that were reported used were distributed to persons at risk of an overdose. Individuals not personally at risk of overdose had higher odds of collecting naloxone at a pharmacy site, compared to other community sites (including harm reduction supply distribution sites, peer led organizations, drop-in centers, and supportive housing sites) (Adjusted Odds Ratio (AOR): 2.69; 95% CI: 2.50-2.90).
conclusionsThis study documents thousands of opioid overdose reversals facilitated through the BC THN program. While those at highest risk of overdose may preferentially access naloxone through community sites, naloxone distribution through pharmacies has allowed the BC THN program to expand dramatically, increasing naloxone availability through longer opening hours on evenings and weekends. and in rural and remote regions. A diversity of naloxone distribution sites and strategies is crucial to prevent rising opioid overdose deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.